On February 10, 2022 Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, reported that it will present a company overview at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 9:00 am ET (Press release, Chemomab, FEB 10, 2022, View Source2022-02-10-Chemomab-Therapeutics-to-Present-at-Aegis-Virtual-Conference" target="_blank" title="View Source2022-02-10-Chemomab-Therapeutics-to-Present-at-Aegis-Virtual-Conference" rel="nofollow">View Source [SID1234607958]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To access the event: click View Source
Chemomab_Logo
View File Download File
Chemomab_Logo
A copy of Chemomab’s presentation will also be available on Chemomab’s website at View Source starting on February 24, 2022.
For additional information on accessing the Chemomab presentation, click on Aegis Virtual Conference Calendar.